Vertex Pharmaceuticals lags biotech sector despite strong revenue beat
Vertex shares have underperformed the broader biotechnology sector over the past year, weighed down by commercialisation hurdles and pipeline setbacks, even as analysts maintain a moderate buy consensus.
Vertex Pharmaceuticals has trailed the broader biotechnology sector over the past year, with shares rising 37.9 per cent compared with the 44.3 per cent return of the VanEck Biotech ETF. The Boston-based firm, which holds a market capitalisation of $139 billion, currently trades 1.4 per cent below its 52-week high of $555.69, a level reached on 25 August.
While the stock has gained 21.9 per cent year-to-date, it has underperformed the sector benchmark, which recorded a 26.8 per cent increase over the same period. Over the past three months, Vertex shares climbed 30.1 per cent, slightly behind the ETF’s 32 per cent gain. The stock has remained above its 200-day moving average since early December 2025 and its 50-day moving average since early June, indicating a persistent bullish trend despite recent relative weakness.
The underperformance is attributed to commercialisation challenges for non-cystic fibrosis therapies, specifically Journavx and Casgevy. Investors have also reacted to pipeline setbacks, including the discontinuation of the non-opioid pain drug VX-993, and ongoing regulatory scrutiny regarding pricing. These factors have tempered sentiment despite the company’s dominant position in cystic fibrosis treatments, anchored by blockbuster products such as Trikafta and Katori.
In its second-quarter results released on 3 August, Vertex reported adjusted earnings per share of $4.73, missing Wall Street estimates of $4.79. However, revenue of $3.3 billion exceeded forecasts of $3.2 billion. The company expects full-year revenue to fall within the range of $13.1 billion to $13.2 billion. Following the report, shares closed down 1.3 per cent.
In the competitive biotechnology landscape, Vertex has outperformed peers such as BioMarin Pharmaceutical, which has seen an 11.1 per cent gain year-to-date and an 11.7 per cent rise over the past 52 weeks. Despite the mixed performance metrics, Wall Street analysts remain reasonably bullish on the stock’s prospects.
The consensus rating from 30 analysts covering the company stands at “Moderate Buy,” with a mean price target of $566.65. This suggests a potential upside of 3.5 per cent from current price levels, reflecting a view that the company’s long-term fundamentals remain intact despite short-term headwinds.
